RAPT Therapeutics, Inc. RAPT
Set alert
58.01 USD 0.00 0.00%
As of Mar 6, 9:30 AM ET
58.01 Day range 58.01
26.50 52-week range 58.02
- YTD
- +71.26%
- 1 year
- +547.38%
- Open
- 58.01
- Prev close
- 58.01
- Mkt cap
- 1.61B
- Vol
- 10.85M
- Avg vol
- 4.25M
- EPS
- -11.06
- P/E
- -44.46
- Div yield
- 0.00%
More statistics
- Low
- 58.01
- High
- 58.01
- Beta
- 0.44
- Inst. own
- 110.57%
- Dividend
- 0.00
2Y chart
Events in this range
- Nov 12, 2024Earnings: -3.76; estimate -0.56; surprise -571.43%
- Mar 6, 2025Earnings: -9.12; estimate -3.6; surprise -153.33%
- May 8, 2025Earnings: -0.64; estimate -2.48; surprise 74.19%
- Jun 17, 2025Split: 1 for 8
- Aug 7, 2025Earnings: -0.65; estimate -0.61; surprise -6.56%
- Nov 6, 2025Earnings: -0.65; estimate -0.88; surprise 26.14%
- Jan 20, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jan 20, 2026Downgrade: TD Cowen · Buy → Hold
- Jan 20, 2026Downgrade: LifeSci Capital · Outperform → Market Perform
- Jan 20, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- Jan 21, 2026Downgrade: Leerink Partners · Outperform → Market Perform
- Jan 21, 2026Downgrade: Barclays · Overweight → Equal-Weight
- Mar 5, 2026Earnings: -9.12; estimate -0.82293; surprise -1008.24%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Feb 6, 2026 | 8 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 21, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| RSI: Overbought | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| RSI: Overbought | Sep 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 27, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| RSI: Overbought | Jul 18, 2025 | 1 year ago |
| SMA: Bullish | Jul 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 26, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| RSI: Overbought | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 20, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Mar 12, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 8, 2025 | 1 year ago |
| SMA: Bullish | Dec 23, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 20, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 18, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 9, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 12, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| RSI: Overbought | Nov 6, 2024 | 1 year ago |
| SMA: Bullish | Oct 29, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 22, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 21, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 18, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 17, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 10, 2024 | 2 years ago |
| RSI: Oversold | Sep 6, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 5, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 21, 2024 | 2 years ago |
| RSI: Oversold | Aug 14, 2024 | 2 years ago |
| RSI: Oversold | Aug 7, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| RSI: Oversold | Jun 7, 2024 | 2 years ago |
| MACD: Buy Signal | May 30, 2024 | 2 years ago |
| RSI: Oversold | May 24, 2024 | 2 years ago |
| MACD: Sell Signal | May 9, 2024 | 2 years ago |
| RSI: Oversold | May 9, 2024 | 2 years ago |
| MACD: Buy Signal | May 3, 2024 | 2 years ago |
Key statistics
- Market cap
- 1.61B
- Enterprise value
- 1.57B
- Trailing P/E
- -44.46
- PEG ratio
- -0.67
- Price / sales
- 0.00
- Price / book
- 10.29
- Beta
- 0.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.27%
Analyst view
Price target (mean) —
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.03.
Financials — quick view
RAPT Revenue — quarterly 0
RAPT Net income — quarterly -17.58M
RAPT EPS — quarterly -0.65
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2026 | Dec 30, 2025 | -0.82293 | -9.12 | -8.30 | -1,008.24% |
| Nov 6, 2025 | Sep 30, 2025 | -0.88 | -0.65 | +0.23 | +26.14% |
| Aug 7, 2025 | Jun 30, 2025 | -0.61 | -0.65 | -0.04 | -6.56% |
| May 8, 2025 | Mar 31, 2025 | -2.48 | -0.64 | +1.84 | +74.19% |
| Mar 6, 2025 | Dec 31, 2024 | -3.60 | -9.12 | -5.52 | -153.33% |
| Nov 12, 2024 | Sep 30, 2024 | -0.56 | -3.76 | -3.20 | -571.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 21, 2026 | Barclays | down | Overweight | Equal-Weight |
| Jan 21, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Jan 20, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jan 20, 2026 | LifeSci Capital | down | Outperform | Market Perform |
| Jan 20, 2026 | TD Cowen | down | Buy | Hold |
| Jan 20, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 67
- Website
- rapt.com
News
- This Biotech Was Quietly Bought Before a $58 Per Share Takeout
- This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
- This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
- Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
- Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
- Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
- Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
- Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
- RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
- Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations
Your note
Sign in to keep a note on RAPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRAUNSTEIN SCOTT N. | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| DOMBKOWSKI ASHLEY L | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| GIORDANO MICHAEL F | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| GRAY MARY ANN | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| KOZICK LINDA | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| LYONS-WILLIAMS LORI | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 10.08% | 2,794,000 | 162.11M | Dec 30, 2025 |
| TCG Crossover Management, LLC | 9.32% | 2,582,408 | 149.83M | Dec 30, 2025 |
| FCPM III Services B.V. | 6.62% | 1,833,333 | 106.37M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 5.93% | 1,642,891 | 95.32M | Dec 30, 2025 |
| RTW Investments LP | 5.91% | 1,637,165 | 94.99M | Dec 30, 2025 |
| Foresite Capital Management VI LLC | 5.64% | 1,562,500 | 90.66M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.98% | 827,036 | 47.98M | Dec 30, 2025 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.98% | 547,644 | 31.77M | Dec 30, 2025 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.99% | 273,226 | 15.85M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 207,602 | 12.05M | Dec 30, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.48% | 131,880 | 7.65M | Dec 30, 2025 |
| -Fidelity SAI Merger Arbitrage Fund | 0.45% | 125,000 | 7.25M | Jan 30, 2026 |